Thursday, 15 September 2022

6-mth T-bill 3.32%

 I applied for $30k of T-bills for the first time using internet banking. Unlike SSB each T-bill application is free of charge.  The yield is announced after the auction and was 3.32% which is a whole lot higher than fixed deposits. Yet the news reports long queues at bank branches to place 2.6-2.7% fixed deposits.


I used OCBC internet banking to apply and I have to say that their system is really good. I got notified by SMS and e-mail really quickly.




Looking at the bond portion of my portfolio, I have 2 SSBs with less than 2.5% interest. For now, it makes sense to redeem them and redeploy the funds into T-bills. I've redeemed one of them and will redeem the other next month.




Wednesday, 7 September 2022

Strategy: Sep 2022

 Using IWDA's price as a proxy for MSCI World (i.e. IWDA tracks MSCI World), my strategy was to enter as it dropped below $75 and to average down at $72 and then at $70.

I began at $74.85 last week and now $71.99 today. I also bought VWRD today at $98.88. Given the lack of panic, I am optimistic for a 'higher low' and that IWDA will hold at $70.

In the meantime, I am in buying mode and will continue to buy this week as valuations are more reasonable at these levels.



Saturday, 3 September 2022

Singapore Stocks I am still buying

 

    




While there is a lot of focus on the US market as well as fairly strong opinions on the internet about how bad the Singapore stock market is, I am nevertheless accumulating two local stocks that derive some of their income from overseas: Comfort Delgro and Ascott Residence Trust. Some geographical diversification of their incomes makes the stocks more attractive than counters that solely derive their income from Singapore.

They are currently in my Medium-sized holdings part of my Portfolio, but I have no issues accumulating more till they are upgraded to "Large."

There may be some negativity due to COVID on the transport and accommodation sectors but that might mean that this is the best time to buy if you believe that these businesses will recover to their pre-pandemic levels.

The management quality of these two companies appears decent enough for me to believe that they will be able to position their business for the post-pandemic recovery. For example, ART's divestment and acquisition strategy suggests that they are repositioning the Trust with a certain vision of the future.

While inflation is certainly a problem, I expect that ART will be able to raise prices to cover its costs. Comfort Delgro operates in perhaps a more 'sensitive' area especially where public transport is concerned but there are mechanisms in place for price increases and this issue is nothing new.


Earnings Per Share

In terms of Earnings per share, ART has actually recovered to pre-pandemic levels:

2019:  9.04

2020: (7.69)

2021:  9.36


As for Comfort Delgro, their EPS certainly looks bad, but it is a case of "No Way Back" or is a recovery in sight? Furthermore, what is the EPS baked into the current price and is the market underestimating CDG? In which case, we can expect price surprises to the upside.


In contrast, Grab is still bleeding badly, as Business Times reported in August 2022:

 "Strong ride-hailing recovery narrowed the net loss for South-east Asian tech giant Grab to US$547 million for the second quarter ended June, compared to the year-ago loss of US$768 million."











Dividends Collected: August 2022

 




STI paid its dividend this month

Tuesday, 30 August 2022

Sep 2022 2.8% $13,500 SSB

I was allocated $13,500 this time round for the September 2.8% SSB. So my last 3 months' allocations are:

  • 2.71% - $18,000
  • 3% - $9,000
  • 2.8% - $13,500

Thursday, 11 August 2022

Dividends Collected: July 2022

 




July is another month where SG companies don't seem to pay dividends

GSK / Haleon : Zantec Litigation

 Both GSK and HLN are falling due to worries about litigation over the Zantec drug.

Technically, HLN has nothing to do with it after demerger but yahoo news has reported that:

Haleon said it has certain indemnification obligations to GSK and Pfizer, “which may include liabilities related to OTC Zantac,” in a prospectus ahead of listing its shares in London last month. That’s while Credit Suisse analysts flagged Haleon’s involvement in Zantac litigation was limited.

Anyway, I bought some more Haleon today. This could be possible falling knife territory or it may be that the market is over-reacting to Haleon's possible exposure to the Zantec Litigation.